Yongkeun Cho
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Yongkeun Cho has a total of 154 co-authors. Here are the top co-authors by number of shared publications:
Dong Heon Yang
Department of Internal Medicine, School of Medicine, Kyungpook National University, Daegu, Republic of Korea
17 shared publicationsHun Sik Park
Kyungpook National University Hospital
15 shared publicationsJang Hoon Lee
Department of Internal Medicine, School of Medicine, Kyungpook National University, Daegu, Republic of Korea
14 shared publicationsMyung Hwan Bae
Department of Internal Medicine, School of Medicine, Kyungpook National University, Daegu, Republic of Korea
14 shared publications- Myung Hwan Bae
Division of Cardiology, Department of Internal Medicine, Kyungpook National University Hospital, Daegu, Korea
14 shared publications - Dong Heon Yang
Division of Cardiology, Department of Internal Medicine, Kyungpook National University, Daegu, Korea
13 shared publications
Latest Publications
- Open Access
- 17 March 2026
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 15 (6) , e045151
Long‐Term Clinical Outcomes of Acute Myocardial Infarction Based on Institutional Experience With IVUS
Background: Intravascular ultrasound (IVUS)‐guided percutaneous coronary intervention improves patient outcomes, yet the impact of a center's IVUS experience on long‐term outcomes remains unclear. We evaluated whether the prognostic association of IVUS‐guided percutaneous coronary intervention in patients with acute myocardial infarction differs based on a center's level of IVUS use. Methods: We retrospectively analyzed 9752 patients with acute myocardial infarction treated with second‐generation drug‐eluting stents from the KAMIR‐NIH (Korean Acute Myocardial Infarction Registry–National Institutes of Health). The primary outcome was 3‐year major adverse cardiovascular events, defined as a composite of all‐cause death, myocardial infarction, and coronary revascularization. The secondary outcome was target‐lesion failure, defined as a composite of cardiac death, target‐vessel myocardial infarction, and ischemia‐driven target lesion revascularization. Centers were classified into higher‐ or lower‐IVUS‐use groups on the basis of median institutional usage (10.3%). Results: In higher‐use centers, IVUS‐guided percutaneous coronary intervention was associated with lower rates of major adverse cardiovascular events (15.3% versus 18.5%, P =0.016) and target‐lesion failure (6.3% versus 8.3%, P =0.039) in propensity score–matched populations. Multivariate Cox analysis confirmed lower risks of major adverse cardiovascular events (hazard ratio [HR], 0.80 [95% CI, 0.69–0.93]; P =0.003) and target‐lesion failure (HR, 0.75 [95% CI, 0.59–0.93]; P =0.01). Conversely, in lower‐use centers, IVUS guidance was not associated with significant differences in major adverse cardiovascular events (15.7% versus 18.6%, P =0.422) or target‐lesion failure (8.9% versus 10.4%, P =0.644). Conclusions: The association of IVUS‐guided percutaneous coronary intervention with lower adverse event rates was more apparent and statistically demonstrable in centers with higher IVUS use. These findings suggest that institutional experience may amplify the observable impact of IVUS guidance, underscoring the potential value of standardized IVUS implementation in acute myocardial infarction management.
- 17 March 2026
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 15 (6) , e045151
Open AccessLong‐Term Clinical Outcomes of Acute Myocardial Infarction Based on Institutional Experience With IVUS
Background: Intravascular ultrasound (IVUS)‐guided percutaneous coronary intervention improves patient outcomes, yet the impact of a center's IVUS experience on long‐term outcomes remains unclear. We evaluated whether the prognostic association of IVUS‐guided percutaneous coronary intervention in patients with acute myocardial infarction differs based on a center's level of IVUS use. Methods: We retrospectively analyzed 9752 patients with acute myocardial infarction treated with second‐generation drug‐eluting stents from the KAMIR‐NIH (Korean Acute Myocardial Infarction Registry–National Institutes of Health). The primary outcome was 3‐year major adverse cardiovascular events, defined as a composite of all‐cause death, myocardial infarction, and coronary revascularization. The secondary outcome was target‐lesion failure, defined as a composite of cardiac death, target‐vessel myocardial infarction, and ischemia‐driven target lesion revascularization. Centers were classified into higher‐ or lower‐IVUS‐use groups on the basis of median institutional usage (10.3%). Results: In higher‐use centers, IVUS‐guided percutaneous coronary intervention was associated with lower rates of major adverse cardiovascular events (15.3% versus 18.5%, P =0.016) and target‐lesion failure (6.3% versus 8.3%, P =0.039) in propensity score–matched populations. Multivariate Cox analysis confirmed lower risks of major adverse cardiovascular events (hazard ratio [HR], 0.80 [95% CI, 0.69–0.93]; P =0.003) and target‐lesion failure (HR, 0.75 [95% CI, 0.59–0.93]; P =0.01). Conversely, in lower‐use centers, IVUS guidance was not associated with significant differences in major adverse cardiovascular events (15.7% versus 18.6%, P =0.422) or target‐lesion failure (8.9% versus 10.4%, P =0.644). Conclusions: The association of IVUS‐guided percutaneous coronary intervention with lower adverse event rates was more apparent and statistically demonstrable in centers with higher IVUS use. These findings suggest that institutional experience may amplify the observable impact of IVUS guidance, underscoring the potential value of standardized IVUS implementation in acute myocardial infarction management.
- Open Access
- 1 January 2024
- Published by XMLink in Korean Circulation Journal
- Vol. 54 (4) , 221-222
Cardiomyopathy Without Amyloid Deposit in Systemic Light Chain Deposition Disease
Park BE, et al. Korean Circ J. 2024 Apr;54(4):221-222. https://doi.org/10.4070/kcj.2024.0022
- 1 January 2024
- Published by XMLink in Korean Circulation Journal
- Vol. 54 (4) , 221-222
Open AccessCardiomyopathy Without Amyloid Deposit in Systemic Light Chain Deposition Disease
Park BE, et al. Korean Circ J. 2024 Apr;54(4):221-222. https://doi.org/10.4070/kcj.2024.0022
- Open Access
- 2 November 2023
- Published by Oxford University Press (OUP) in EP Europace
- Vol. 25 (11)
Identification of concealed cardiomyopathy using next-generation sequencing–based genetic testing in Korean patients initially diagnosed with idiopathic ventricular fibrillation
Idiopathic ventricular fibrillation (IVF) is a disease in which the cause of ventricular fibrillation cannot be identified despite comprehensive clinical evaluation. This study aimed to investigate the clinical yield and implications of genetic testing for IVF. This study was based on the multi-centre inherited arrhythmia syndrome registry in South Korea from 2014 to 2017. Next-generation sequencing–based genetic testing was performed that included 174 genes previously linked to cardiovascular disease. A total of 96 patients were clinically diagnosed with IVF. The mean age of the onset was 41.2 ± 12.7 years, and 79 patients were males (82.3%). Of these, 74 underwent genetic testing and four (5.4%) of the IVF probands had pathogenic or likely pathogenic variants (each having one of MYBPC3, MYH7, DSP, and TNNI3). All pathogenic or likely pathogenic variants were located in genes with definite evidence of a cardiomyopathy phenotype, either hypertrophic cardiomyopathy or arrhythmogenic right ventricular cardiomyopathy. Next-generation sequencing–based genetic testing identified pathogenic or likely pathogenic variants in 5.4% of patients initially diagnosed with IVF, suggesting that genetic testing with definite evidence genes of cardiomyopathy may enable molecular diagnosis in a minority of patients with IVF. Further clinical evaluation and follow-up of patients with IVF with positive genotypes are needed to unveil concealed phenotypes, such as the pre-clinical phase of cardiomyopathy. Concealed channelopathy and cardiomyopathy in IVF. IVF, idiopathic ventricular fibrillation; NGS, next-generation sequencing; P/LP, pathogenic or likely pathogenic; BrS, Brugada Syndrome; LQTS, long QT syndrome; CPVT, cathecholaminergic polymorphic ventricular tachycardia; ARVC, arrhythmogenic right ventricular cardiomyopathy; HCM, hypertrophic cardiomyopathy; DCM, dilated cardiomyopathy.
- 2 November 2023
- Published by Oxford University Press (OUP) in EP Europace
- Vol. 25 (11)
Open AccessIdentification of concealed cardiomyopathy using next-generation sequencing–based genetic testing in Korean patients initially diagnosed with idiopathic ventricular fibrillation
Idiopathic ventricular fibrillation (IVF) is a disease in which the cause of ventricular fibrillation cannot be identified despite comprehensive clinical evaluation. This study aimed to investigate the clinical yield and implications of genetic testing for IVF. This study was based on the multi-centre inherited arrhythmia syndrome registry in South Korea from 2014 to 2017. Next-generation sequencing–based genetic testing was performed that included 174 genes previously linked to cardiovascular disease. A total of 96 patients were clinically diagnosed with IVF. The mean age of the onset was 41.2 ± 12.7 years, and 79 patients were males (82.3%). Of these, 74 underwent genetic testing and four (5.4%) of the IVF probands had pathogenic or likely pathogenic variants (each having one of MYBPC3, MYH7, DSP, and TNNI3). All pathogenic or likely pathogenic variants were located in genes with definite evidence of a cardiomyopathy phenotype, either hypertrophic cardiomyopathy or arrhythmogenic right ventricular cardiomyopathy. Next-generation sequencing–based genetic testing identified pathogenic or likely pathogenic variants in 5.4% of patients initially diagnosed with IVF, suggesting that genetic testing with definite evidence genes of cardiomyopathy may enable molecular diagnosis in a minority of patients with IVF. Further clinical evaluation and follow-up of patients with IVF with positive genotypes are needed to unveil concealed phenotypes, such as the pre-clinical phase of cardiomyopathy. Concealed channelopathy and cardiomyopathy in IVF. IVF, idiopathic ventricular fibrillation; NGS, next-generation sequencing; P/LP, pathogenic or likely pathogenic; BrS, Brugada Syndrome; LQTS, long QT syndrome; CPVT, cathecholaminergic polymorphic ventricular tachycardia; ARVC, arrhythmogenic right ventricular cardiomyopathy; HCM, hypertrophic cardiomyopathy; DCM, dilated cardiomyopathy.
- Open Access
- 14 August 2023
- Published by Korean Society for Thoracic and Cardiovascular Surgery in Journal of Chest Surgery
- Vol. 56 (6) , 414-419
Bilateral Cardiac Sympathetic Denervation as a Safe Therapeutic Option for Ventricular Arrhythmias
Soo Jung Park, M.D., Deok Heon Lee, M.D., Ph.D., Youngok Lee, M.D., Ph.D., Hanna Jung, M.D., Ph.D., Yongkeun Cho, M.D., Ph.D.. J Chest Surg 2023;56:414-9. https://doi.org/10.5090/jcs.23.055
- 14 August 2023
- Published by Korean Society for Thoracic and Cardiovascular Surgery in Journal of Chest Surgery
- Vol. 56 (6) , 414-419
Open AccessBilateral Cardiac Sympathetic Denervation as a Safe Therapeutic Option for Ventricular Arrhythmias
Soo Jung Park, M.D., Deok Heon Lee, M.D., Ph.D., Youngok Lee, M.D., Ph.D., Hanna Jung, M.D., Ph.D., Yongkeun Cho, M.D., Ph.D.. J Chest Surg 2023;56:414-9. https://doi.org/10.5090/jcs.23.055
- 1 June 2023
- Published by Elsevier in Atherosclerosis
- Vol. 384, 117154
Sex differences in the association between minor nonspecific ST-segment and T-wave abnormalities and coronary artery calcification
- 1 June 2023
- Published by Elsevier in Atherosclerosis
- Vol. 384, 117154
Sex differences in the association between minor nonspecific ST-segment and T-wave abnormalities and coronary artery calcification
- Open Access
- 10 January 2023
- Published by Wiley in Annals of Noninvasive Electrocardiology
- Vol. 28 (2) , e13036
Predictors of stroke or systemic embolism in patients with non‐valvular atrial fibrillation with CHA2DS2‐VASc score of 0
Background: Anticoagulant therapy has been important for stroke prevention in patients with atrial fibrillation (AF). However, it was not recommended due to its relatively higher risk of bleeding than its lower risk of stroke in patients with a CHA2DS2‐VASc score of 0.Hypothesis: This study aimed to evaluate the predictors of stroke in AF patients with very low risk of stroke.Methods: Between 1990 and 2020, 542 patients with non‐valvular AF (NVAF) with a CHA2DS2‐VASc score of 0 followed up for at least 6 months were enrolled. Patients with only being woman as a risk factor were included as a CHA2DS2‐VASc score of 0 in this study. The primary outcome was stroke or systemic embolism.Results: The primary outcome rate was 0.78%/year. In Cox hazard model, age of ≥50 years at diagnosis (hazard ratio [HR] 6.710, 95% confidence interval [CI] 1.811–24.860, p = .004), LVEDD of ≥46 mm (HR 4.513, 95% CI 1.038–19.626, p = .045), and non‐paroxysmal AF (HR 5.575, 95% CI 1.621–19.175, p = .006) were identified as independent predictors of stroke or systemic embolism. Patients with all three independent predictors had a higher risk of stroke or systemic embolism (4.21%/year), whereas those without did not have a stroke or systemic embolism.Conclusion: The annual stroke or systemic embolism rate in NVAF patients with CHA2DS2‐VASc score of 0 was 0.78%/year, and age at AF diagnosis, LVEDD, and non‐paroxysmal AF were independent predictors of stroke or systemic embolism in patients considered to have a very low risk of stroke.
- 10 January 2023
- Published by Wiley in Annals of Noninvasive Electrocardiology
- Vol. 28 (2) , e13036
Open AccessPredictors of stroke or systemic embolism in patients with non‐valvular atrial fibrillation with CHA2DS2‐VASc score of 0
Background: Anticoagulant therapy has been important for stroke prevention in patients with atrial fibrillation (AF). However, it was not recommended due to its relatively higher risk of bleeding than its lower risk of stroke in patients with a CHA2DS2‐VASc score of 0.Hypothesis: This study aimed to evaluate the predictors of stroke in AF patients with very low risk of stroke.Methods: Between 1990 and 2020, 542 patients with non‐valvular AF (NVAF) with a CHA2DS2‐VASc score of 0 followed up for at least 6 months were enrolled. Patients with only being woman as a risk factor were included as a CHA2DS2‐VASc score of 0 in this study. The primary outcome was stroke or systemic embolism.Results: The primary outcome rate was 0.78%/year. In Cox hazard model, age of ≥50 years at diagnosis (hazard ratio [HR] 6.710, 95% confidence interval [CI] 1.811–24.860, p = .004), LVEDD of ≥46 mm (HR 4.513, 95% CI 1.038–19.626, p = .045), and non‐paroxysmal AF (HR 5.575, 95% CI 1.621–19.175, p = .006) were identified as independent predictors of stroke or systemic embolism. Patients with all three independent predictors had a higher risk of stroke or systemic embolism (4.21%/year), whereas those without did not have a stroke or systemic embolism.Conclusion: The annual stroke or systemic embolism rate in NVAF patients with CHA2DS2‐VASc score of 0 was 0.78%/year, and age at AF diagnosis, LVEDD, and non‐paroxysmal AF were independent predictors of stroke or systemic embolism in patients considered to have a very low risk of stroke.
- Open Access
- 1 January 2023
- Published by XMLink in Journal of Korean Medical Science
- Vol. 38 (46) , e399
Impact of Positron Emission Tomography Viability Imaging: Guided Revascularizations on Clinical Outcomes in Patients With Myocardial Scar on Single-Photon Emission Computed Tomography Scans
Park JS, et al. J Korean Med Sci. 2023 Nov;38:e399. https://doi.org/10.3346/jkms.2023.38.e399
- 1 January 2023
- Published by XMLink in Journal of Korean Medical Science
- Vol. 38 (46) , e399
Open AccessImpact of Positron Emission Tomography Viability Imaging: Guided Revascularizations on Clinical Outcomes in Patients With Myocardial Scar on Single-Photon Emission Computed Tomography Scans
Park JS, et al. J Korean Med Sci. 2023 Nov;38:e399. https://doi.org/10.3346/jkms.2023.38.e399
- Open Access
- 1 January 2023
- Published by XMLink in Korean Circulation Journal
- Vol. 53 (10) , 693-707
Clinical and Genetic Features of Korean Inherited Arrhythmia Probands
Jeong JH, et al. Korean Circ J. 2023 Aug;53:e56. https://doi.org/10.4070/kcj.2023.0083
- 1 January 2023
- Published by XMLink in Korean Circulation Journal
- Vol. 53 (10) , 693-707
Open AccessClinical and Genetic Features of Korean Inherited Arrhythmia Probands
Jeong JH, et al. Korean Circ J. 2023 Aug;53:e56. https://doi.org/10.4070/kcj.2023.0083
- Open Access
- 1 January 2022
- Published by XMLink in Journal of Korean Medical Science
- Vol. 37 (21) , e167
Impact of the COVID-19 Pandemic on Patient Delay and Clinical Outcomes for Patients With Acute Myocardial Infarction
Choi H, et al. J Korean Med Sci. 2022 May;37(21):e167. https://doi.org/10.3346/jkms.2022.37.e167
- 1 January 2022
- Published by XMLink in Journal of Korean Medical Science
- Vol. 37 (21) , e167
Open AccessImpact of the COVID-19 Pandemic on Patient Delay and Clinical Outcomes for Patients With Acute Myocardial Infarction
Choi H, et al. J Korean Med Sci. 2022 May;37(21):e167. https://doi.org/10.3346/jkms.2022.37.e167
- Open Access
- 31 October 2021
- Published by Yeungnam University College of Medicine in Journal of Yeungnam Medical Science
- Vol. 38 (4) , 337-343
Prognostic impact of chromogranin A in patients with acute heart failure
Background: Chromogranin A (CgA) levels have been reported to predict mortality in patients with heart failure. However, information on the prognostic value and clinical availability of CgA is limited. We compared the prognostic value of CgA to that of previously proven natriuretic peptide biomarkers in patients with acute heart failure.Methods: We retrospectively evaluated 272 patients (mean age, 68.5±15.6 years; 62.9% male) who underwent CgA test in the acute stage of heart failure hospitalization between June 2017 and June 2018. The median follow-up period was 348 days. Prognosis was assessed using the composite events of 1-year death and heart failure hospitalization.Results: In-hospital mortality rate during index admission was 7.0% (n=19). During the 1-year follow-up, a composite event rate was observed in 12.1% (n=33) of the patients. The areas under the receiver-operating characteristic curves for predicting 1-year adverse events were 0.737 and 0.697 for N-terminal pro-B-type natriuretic peptide (NT-proBNP) and CgA, respectively. During follow-up, patients with high CgA levels (>158 pmol/L) had worse outcomes than those with low CgA levels (≤158 pmol/L) (85.2% vs. 58.6%, p<0.001). When stratifying the patients into four subgroups based on CgA and NT-proBNP levels, patients with high NT-proBNP and high CgA had the worst outcome. CgA had an incremental prognostic value when added to the combination of NT-proBNP and clinically relevant risk factors.Conclusion: The prognostic power of CgA was comparable to that of NT-proBNP in patients with acute heart failure. The combination of CgA and NT-proBNP can improve prognosis prediction in these patients.
- 31 October 2021
- Published by Yeungnam University College of Medicine in Journal of Yeungnam Medical Science
- Vol. 38 (4) , 337-343
Open AccessPrognostic impact of chromogranin A in patients with acute heart failure
Background: Chromogranin A (CgA) levels have been reported to predict mortality in patients with heart failure. However, information on the prognostic value and clinical availability of CgA is limited. We compared the prognostic value of CgA to that of previously proven natriuretic peptide biomarkers in patients with acute heart failure.Methods: We retrospectively evaluated 272 patients (mean age, 68.5±15.6 years; 62.9% male) who underwent CgA test in the acute stage of heart failure hospitalization between June 2017 and June 2018. The median follow-up period was 348 days. Prognosis was assessed using the composite events of 1-year death and heart failure hospitalization.Results: In-hospital mortality rate during index admission was 7.0% (n=19). During the 1-year follow-up, a composite event rate was observed in 12.1% (n=33) of the patients. The areas under the receiver-operating characteristic curves for predicting 1-year adverse events were 0.737 and 0.697 for N-terminal pro-B-type natriuretic peptide (NT-proBNP) and CgA, respectively. During follow-up, patients with high CgA levels (>158 pmol/L) had worse outcomes than those with low CgA levels (≤158 pmol/L) (85.2% vs. 58.6%, p<0.001). When stratifying the patients into four subgroups based on CgA and NT-proBNP levels, patients with high NT-proBNP and high CgA had the worst outcome. CgA had an incremental prognostic value when added to the combination of NT-proBNP and clinically relevant risk factors.Conclusion: The prognostic power of CgA was comparable to that of NT-proBNP in patients with acute heart failure. The combination of CgA and NT-proBNP can improve prognosis prediction in these patients.